metformin has been researched along with Cancer of Mouth in 32 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression." | 3.01 | Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma. ( Liu, J; Qiao, X; Zhao, J, 2023) |
| "Oral squamous cell carcinoma (OSCC) is considered as the sixth most common cancer worldwide characterized by high invasiveness, high metastasis rate and high mortality." | 1.91 | Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing. ( Chen, C; Ji, M; Li, X; Lv, Y; Ma, X; Qi, Y; Wang, Y; Xing, D; Xu, W; Zhang, J; Zhang, W; Zhao, J; Zhou, C, 2023) |
| "However, the role of IL-1RA in oral squamous cell carcinoma (OSCC), in particular the underlying mechanisms, remains to be elucidated." | 1.91 | IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway. ( Chan, LP; Chen, YK; Hu, SC; Hung, AC; Lo, S; Nguyen, HDH; Wang, YM; Wang, YY; Yuan, SF, 2023) |
| "Metformin is a potential anticancer drug." | 1.72 | Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma. ( Nie, HQ; Shao, SH; Su, T; Wang, WM; Yang, SS; Zhang, J, 2022) |
| "Metformin is an antidiabetic drug that has been reported to have an inhibitory effect on different types of cancers, including oral squamous cell carcinoma (OSCC)." | 1.62 | Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells. ( Feng, X; Fu, X; Gu, W; Tian, H; Wang, Y; Wen, Y; Zhang, Y, 2021) |
| "To investigate the impact of type 2 diabetes mellitus (T2DM) and metformin treatment on the prognosis of oral squamous cell carcinoma (OSCC) patients received radical surgical treatment." | 1.56 | Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses. ( Chen, W; Hu, X; Huang, D; Huang, L; Mao, T; Shu, Y; Su, T; Wang, C; Wang, Z; Xia, K; Xiong, H; Yang, L; Yu, J, 2020) |
| "Metformin is an antidiabetic drug widely used for the treatment of type 2 diabetes." | 1.51 | Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway. ( Bindoff, LA; Costea, DE; Fan, Y; Gao, Z; Li, L; Liang, X; Zhang, Z, 2019) |
| "Oral squamous cell carcinoma (OSCC) is the most common and aggressive epithelial tumor in the head and neck region with a rising incidence." | 1.51 | Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma. ( Cheng, B; Deng, M; Fan, Z; He, L; He, Y; Huang, Y; Ping, F; Tai, S; Xia, J; Zhang, C, 2019) |
| "Metformin was administered orally to mice to test effects on immunohistochemical markers in xenografts." | 1.48 | Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts. ( Curry, J; Domingo-Vidal, M; Lin, Z; Martinez-Outschoorn, U; Roche, M; Tassone, P; Tuluc, M; Whitaker-Menezes, D, 2018) |
| "Metformin has been shown to protect against a variety of specific diseases, including cancer." | 1.46 | Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. ( Chen, CH; Chien, CY; Chiu, TJ; Chuang, HC; Fang, FM; Huang, CC; Luo, SD; Shiu, LY; Su, LJ; Tsai, HT, 2017) |
| "Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM)." | 1.46 | Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. ( Blitzer, A; Lerner, MZ; Mor, N; Paek, H; Strome, M, 2017) |
| "Patients with type 2 diabetes mellitus at an onset age of 25-74 years during 1999-2005 and newly treated with either metformin (n = 288198, "ever users of metformin") or other antidiabetic drugs (n = 16263, "never users of metformin") were followed for at least 6 months for oral cancer until December 31, 2011." | 1.43 | Metformin may reduce oral cancer risk in patients with type 2 diabetes. ( Tseng, CH, 2016) |
| "Metformin was reported to be effective against various cancers as it inhibits cell proliferation by activating AMPK, and inhibiting mTOR and HIF-1α." | 1.43 | Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. ( Ferdous, T; Harada, K; Harada, T; Ueyama, Y, 2016) |
| "Metformin is a biguanide, belonging to the oral hypoglycemic agents and is a widely used in the treatment of type 2 diabetes." | 1.43 | Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma. ( de Carvalho Fraga, CA; de Freitas Teles, L; de Jesus, SF; de Paula, AM; de Souza, MG; Farias, LC; Feltenberger, JD; Gomez, RS; Guimarães, AL; Guimarães, TA; Orsini, LA; Santos, ES; Santos, SH, 2016) |
| "Most squamous cell carcinomas of the head and neck (HNSCC) exhibit a persistent activation of the PI3K-mTOR signaling pathway." | 1.42 | Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. ( Carey, TE; Ferris, RL; Gangane, N; Gutkind, JS; Komarck, CM; Madera, D; Martin, D; McHugh, JB; Molinolo, AA; Schneider, A; Seethala, RR; Vitale-Cross, L; Walline, HM; William, WN, 2015) |
| "Metformin could inhibit the growth of OSCC cell line (HSC-3, HSC-4) by reducing cell proliferation and increasing cell apoptosis in vitro and in vivo." | 1.42 | [The inhibitory effect of metformin on oral squamous cell carcinoma]. ( Ji, N; Li, J; Wang, L; Wang, Z; Zhao, X; Zhou, Y, 2015) |
| "Head and neck squamous cell carcinoma (HNSCC) is a major public health concern." | 1.38 | Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. ( Chen, W; Gutkind, JS; Martin, D; Maruyama, T; Molinolo, AA; Patel, V; Schneider, A; Vitale-Cross, L; Younis, RH, 2012) |
| "Metformin treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells." | 1.38 | In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. ( Chen, F; Hu, D; Hu, S; Luo, Q; Sun, Z; Yan, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 16 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, MT | 1 |
| Choe, HC | 1 |
| Kim, BH | 1 |
| Ahn, SG | 1 |
| Wang, WM | 1 |
| Yang, SS | 1 |
| Shao, SH | 1 |
| Nie, HQ | 1 |
| Zhang, J | 3 |
| Su, T | 3 |
| Sahni, V | 1 |
| Kumar, A | 1 |
| Gupta, S | 1 |
| Sharma, S | 1 |
| Lin, YC | 1 |
| Chen, BS | 1 |
| Zhu, L | 1 |
| Deng, Y | 1 |
| Ji, T | 1 |
| Zhou, H | 1 |
| Liu, W | 1 |
| Shete, MB | 1 |
| Deshpande, AS | 1 |
| Shende, PK | 1 |
| Ji, M | 2 |
| Lv, Y | 2 |
| Chen, C | 2 |
| Xing, D | 2 |
| Zhou, C | 2 |
| Zhao, J | 3 |
| Qi, Y | 2 |
| Wang, Y | 3 |
| Ma, X | 2 |
| Xu, W | 2 |
| Zhang, W | 2 |
| Li, X | 2 |
| Yuan, SF | 1 |
| Wang, YM | 1 |
| Chan, LP | 1 |
| Hung, AC | 1 |
| Nguyen, HDH | 1 |
| Chen, YK | 1 |
| Hu, SC | 1 |
| Lo, S | 1 |
| Wang, YY | 1 |
| Liu, J | 1 |
| Qiao, X | 1 |
| Patil, S | 1 |
| Hu, X | 2 |
| Xiong, H | 1 |
| Chen, W | 2 |
| Huang, L | 1 |
| Mao, T | 2 |
| Yang, L | 1 |
| Wang, C | 1 |
| Huang, D | 1 |
| Wang, Z | 2 |
| Yu, J | 1 |
| Shu, Y | 1 |
| Xia, K | 1 |
| Liang, Y | 1 |
| Tian, R | 1 |
| Wang, J | 1 |
| Shan, Y | 1 |
| Gao, H | 1 |
| Xie, C | 1 |
| Li, J | 2 |
| Zhang, L | 1 |
| Xu, M | 1 |
| Gu, S | 1 |
| Wei, J | 1 |
| Huang, J | 1 |
| Kuang, Y | 1 |
| Li, Y | 1 |
| Zhong, D | 1 |
| Song, J | 1 |
| Chen, H | 1 |
| Sa, G | 1 |
| Li, L | 2 |
| He, S | 1 |
| Wu, T | 1 |
| Zhang, Y | 1 |
| Feng, X | 1 |
| Tian, H | 1 |
| Fu, X | 1 |
| Gu, W | 1 |
| Wen, Y | 1 |
| Huang, DN | 1 |
| Chen, WX | 1 |
| Xiong, HF | 1 |
| Chen, CH | 1 |
| Tsai, HT | 1 |
| Chuang, HC | 1 |
| Shiu, LY | 1 |
| Su, LJ | 1 |
| Chiu, TJ | 1 |
| Luo, SD | 1 |
| Fang, FM | 1 |
| Huang, CC | 1 |
| Chien, CY | 1 |
| Siddappa, G | 1 |
| Kulsum, S | 1 |
| Ravindra, DR | 1 |
| Kumar, VV | 1 |
| Raju, N | 1 |
| Raghavan, N | 1 |
| Sudheendra, HV | 1 |
| Sharma, A | 1 |
| Sunny, SP | 1 |
| Jacob, T | 1 |
| Kuruvilla, BT | 1 |
| Benny, M | 1 |
| Antony, B | 1 |
| Seshadri, M | 1 |
| Lakshminarayan, P | 1 |
| Hicks, W | 1 |
| Suresh, A | 1 |
| Kuriakose, MA | 1 |
| Tassone, P | 1 |
| Domingo-Vidal, M | 1 |
| Whitaker-Menezes, D | 1 |
| Lin, Z | 1 |
| Roche, M | 1 |
| Tuluc, M | 1 |
| Martinez-Outschoorn, U | 1 |
| Curry, J | 1 |
| Basile, JR | 2 |
| Czerninski, R | 1 |
| Zhang, Z | 1 |
| Liang, X | 1 |
| Fan, Y | 1 |
| Gao, Z | 1 |
| Bindoff, LA | 1 |
| Costea, DE | 1 |
| He, Y | 1 |
| Tai, S | 1 |
| Deng, M | 1 |
| Fan, Z | 1 |
| Ping, F | 1 |
| He, L | 1 |
| Zhang, C | 1 |
| Huang, Y | 1 |
| Cheng, B | 1 |
| Xia, J | 1 |
| Madera, D | 1 |
| Vitale-Cross, L | 2 |
| Martin, D | 2 |
| Schneider, A | 3 |
| Molinolo, AA | 2 |
| Gangane, N | 1 |
| Carey, TE | 1 |
| McHugh, JB | 1 |
| Komarck, CM | 1 |
| Walline, HM | 1 |
| William, WN | 1 |
| Seethala, RR | 1 |
| Ferris, RL | 1 |
| Gutkind, JS | 2 |
| Wang, L | 1 |
| Zhao, X | 1 |
| Ji, N | 1 |
| Zhou, Y | 1 |
| Tseng, CH | 1 |
| Wang, F | 1 |
| Xu, J | 1 |
| Liu, H | 1 |
| Liu, Z | 1 |
| Xia, F | 1 |
| Harada, K | 1 |
| Ferdous, T | 1 |
| Harada, T | 1 |
| Ueyama, Y | 1 |
| Guimarães, TA | 1 |
| Farias, LC | 1 |
| Santos, ES | 1 |
| de Carvalho Fraga, CA | 1 |
| Orsini, LA | 1 |
| de Freitas Teles, L | 1 |
| Feltenberger, JD | 1 |
| de Jesus, SF | 1 |
| de Souza, MG | 1 |
| Santos, SH | 1 |
| de Paula, AM | 1 |
| Gomez, RS | 1 |
| Guimarães, AL | 1 |
| Lerner, MZ | 1 |
| Mor, N | 1 |
| Paek, H | 1 |
| Blitzer, A | 1 |
| Strome, M | 1 |
| Younis, RH | 2 |
| Maruyama, T | 1 |
| Patel, V | 1 |
| Patel, H | 1 |
| Ord, RA | 1 |
| Luo, Q | 1 |
| Hu, D | 1 |
| Hu, S | 1 |
| Yan, M | 1 |
| Sun, Z | 1 |
| Chen, F | 1 |
1 review available for metformin and Cancer of Mouth
| Article | Year |
|---|---|
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2023 |
31 other studies available for metformin and Cancer of Mouth
| Article | Year |
|---|---|
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani | 2022 |
Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; ErbB Rece | 2022 |
Metformin and oral cancer.
Topics: Humans; Hypoglycemic Agents; Metformin; Mouth Neoplasms | 2022 |
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; | 2022 |
Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
Topics: Cell Transformation, Neoplastic; Chemoprevention; Humans; Leukoplakia, Oral; Metformin; Mouth Neopla | 2022 |
Nanostructured lipid carrier-loaded metformin hydrochloride: Design, optimization, characterization, assessment of cytotoxicity and ROS evaluation.
Topics: Drug Carriers; Humans; Lipids; Metformin; Mouth Neoplasms; Nanostructures; Particle Size; Reactive O | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D | 2023 |
Metformin treatment decreases the expression of cancer stem cell marker CD44 and stemness related gene expression in primary oral cancer cells.
Topics: Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Kruppel-Like | 2020 |
Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
Topics: Carcinoma, Squamous Cell; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypog | 2020 |
Melanotic neuroectodermal tumor of infancy successfully treated with metformin: A case report.
Topics: Combined Modality Therapy; Female; Humans; Hypoglycemic Agents; Infant; Magnetic Resonance Imaging; | 2020 |
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2021 |
In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T | 2021 |
Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; H | 2021 |
[Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment].
Topics: Carcinoma, Squamous Cell; Humans; Male; Metformin; Mouth Neoplasms; Prognosis; Squamous Cell Carcino | 2021 |
Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A.
Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; D | 2017 |
Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.
Topics: 4-Nitroquinoline-1-oxide; AC133 Antigen; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; C | 2017 |
Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Caveolin 1; Cell Culture Techniques; Disease Models, A | 2018 |
Repurposing existing medications in oncology and their potential role in oral cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Repositioning; Humans; Hydroxymethylglutaryl-CoA Reduc | 2019 |
Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Cell Surviva | 2019 |
Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Case-Control Studies; Cell Cycle; C | 2015 |
[The inhibitory effect of metformin on oral squamous cell carcinoma].
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow | 2015 |
Metformin may reduce oral cancer risk in patients with type 2 diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hyp | 2016 |
Metformin induces apoptosis by microRNA-26a-mediated downregulation of myeloid cell leukaemia-1 in human oral cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplast | 2016 |
Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Dru | 2016 |
Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Death; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Mov | 2016 |
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human | 2017 |
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carcinogens; Carcinoma, Squamous Ce | 2012 |
Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.
Topics: AMP-Activated Protein Kinases; Anticarcinogenic Agents; Blotting, Western; Carcinoma, Squamous Cell; | 2013 |
In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Li | 2012 |